Relevant bibliographies by topics / Immunological adjuvants

Academic literature on the topic 'Immunological adjuvants'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 August 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immunological adjuvants.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immunological adjuvants"

Correa, Victor Araujo, Amanda Izeli Portilho, and Elizabeth De Gaspari. "Immunological Effects of Dimethyldioctadecylammonium Bromide and Saponin as Adjuvants for Outer Membrane Vesicles from Neisseria meningitidis." Diseases 10, no. 3 (July 19, 2022): 46. http://dx.doi.org/10.3390/diseases10030046.

Full text

Abstract:

The meningococcal disease is a global health threat, but is preventable through vaccination. Adjuvants improve meningococcal vaccines and are able to trigger different aspects of the immune response. The present work evaluated the immune response of mice against Neisseria meningitidis outer membrane vesicles (OMV) complexed with the adjuvants aluminium hydroxide (AH), via subcutaneous route; and dimethyldioctadecylammonium bromide (DDA) or Saponin (Sap), via intranasal/subcutaneous routes. ELISA demonstrated that all adjuvants increased IgG titers after the booster dose, remaining elevated for 18 months. Additionally, adjuvants increased the avidity of the antibodies and the bactericidal titer: OMVs alone were bactericidal until 1:4 dilution but, when adjuvanted by Alum, DDA or Sap, it increased to 1/32. DDA and Sap increased all IgG isotypes, while AH improved IgG1 and IgG2a levels. Thus, Sap led to the recognition of more proteins in Immunoblot, followed by DDA and AH. Sap and AH induced higher IL-4 and IL-17 release, respectively. The use of adjuvants improved both cellular and humoral immune response, however, each adjuvant contributed to particular parameters. This demonstrates the importance of studying different adjuvant options and their suitability to stimulate different immune mechanisms, modulating the immune response.

APA, Harvard, Vancouver, ISO, and other styles

Martiñón, Susana, Angel Cisneros, Sergio Villicaña, Ricardo Hernández-Miramontes, Edgar Mixcoha, and Psyché Calderón-Vargas. "Chemical and Immunological Characteristics of Aluminum-Based, Oil-Water Emulsion, and Bacterial-Origin Adjuvants." Journal of Immunology Research 2019 (May 8, 2019): 1–9. http://dx.doi.org/10.1155/2019/3974127.

Full text

Abstract:

Adjuvants are a diverse family of substances whose main objective is to increase the strength, quality, and duration of the immune response caused by vaccines. The most commonly used adjuvants are aluminum-based, oil-water emulsion, and bacterial-origin adjuvants. In this paper, we will discuss how the election of adjuvants is important for the adjuvant-mediated induction of immunity for different types of vaccines. Aluminum-based adjuvants are the most commonly used, the safest, and have the best efficacy, due to the triggering of a strong humoral response, albeit generating a weak induction of cell-mediated immune response. Freund’s adjuvant is the most widely used oil-water emulsion adjuvant in animal trials; it stimulates inflammation and causes aggregation and precipitation of soluble protein antigens that facilitate the uptake by antigen-presenting cells (APCs). Adjuvants of bacterial origin, such as flagellin,E. colimembranes, and monophosphoryl lipid A (MLA), are known to potentiate immune responses, but their safety and risks are the main concern of their clinical use. This minireview summarizes the mechanisms that classic and novel adjuvants produce to stimulate immune responses.

APA, Harvard, Vancouver, ISO, and other styles

Trier, Nicole H., Esin Güven, Kristin Skogstrand, Evaldas Ciplys, Rimantas Slibinskas, and Gunnar Houen. "Comparison of immunological adjuvants." APMIS 127, no. 9 (July 26, 2019): 635–41. http://dx.doi.org/10.1111/apm.12976.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Heath, A. W., and J. H. L. Playfair. "Cytokines as immunological adjuvants." Vaccine 10, no. 7 (January 1992): 427–34. http://dx.doi.org/10.1016/0264-410x(92)90389-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Borek, F. "Immunological adjuvants and vaccines." Journal of Immunological Methods 135, no. 1-2 (December 1990): 293. http://dx.doi.org/10.1016/0022-1759(90)90286-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Stewart-Tull, D. "Symposium on immunological adjuvants." Vaccine 3, no. 2 (June 1985): 152–57. http://dx.doi.org/10.1016/0264-410x(85)90092-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Kim, Jeremiah Y., Matthew G. Rosenberger, Nakisha S. Rutledge, and Aaron P. Esser-Kahn. "Next-Generation Adjuvants: Applying Engineering Methods to Create and Evaluate Novel Immunological Responses." Pharmaceutics 15, no. 6 (June 8, 2023): 1687. http://dx.doi.org/10.3390/pharmaceutics15061687.

Full text

Abstract:

Adjuvants are a critical component of vaccines. Adjuvants typically target receptors that activate innate immune signaling pathways. Historically, adjuvant development has been laborious and slow, but has begun to accelerate over the past decade. Current adjuvant development consists of screening for an activating molecule, formulating lead molecules with an antigen, and testing this combination in an animal model. There are very few adjuvants approved for use in vaccines, however, as new candidates often fail due to poor clinical efficacy, intolerable side effects, or formulation limitations. Here, we consider new approaches using tools from engineering to improve next-generation adjuvant discovery and development. These approaches will create new immunological outcomes that will be evaluated with novel diagnostic tools. Potential improved immunological outcomes include reduced vaccine reactogenicity, tunable adaptive responses, and enhanced adjuvant delivery. Evaluations of these outcomes can leverage computational approaches to interpret “big data” obtained from experimentation. Applying engineering concepts and solutions will provide alternative perspectives, further accelerating the field of adjuvant discovery.

APA, Harvard, Vancouver, ISO, and other styles

Yan, Yu, Dan Yao, and Xiaoyu Li. "Immunological Mechanism and Clinical Application of PAMP Adjuvants." Recent Patents on Anti-Cancer Drug Discovery 16, no. 1 (May 25, 2021): 30–43. http://dx.doi.org/10.2174/1574892816666210201114712.

Full text

Abstract:

Background: The host innate immune system can recognize Pathogen-Associated Molecular Patterns (PAMPs) through Pattern Recognition Receptors (PRRs), thereby initiating innate immune responses and subsequent adaptive immune responses. PAMPs can be developed as a vaccine adjuvant for modulating and optimizing antigen-specific immune responses, especially in combating viral infections and tumor therapy. Although several PAMP adjuvants have been successfully developed they are still lacking in general, and many of them are in the preclinical exploration stage. Objective: This review summarizes the research progress and development direction of PAMP adjuvants, focusing on their immune mechanisms and clinical applications. Methods: PubMed, Scopus, and Google Scholar were screened for this information. We highlight the immune mechanisms and clinical applications of PAMP adjuvants. Results: Because of the differences in receptor positions, specific immune cells targets, and signaling pathways, the detailed molecular mechanism and pharmacokinetic properties of one agonist cannot be fully generalized to another agonist, and each PAMP should be studied separately. In addition, combination therapy and effective integration of different adjuvants can increase the additional efficacy of innate and adaptive immune responses. Conclusion: The mechanisms by which PAMPs exert adjuvant functions are diverse. With continuous discovery in the future, constant adjustments should be made to build new understandings. At present, the goal of therapeutic vaccination is to induce T cells that can specifically recognize and eliminate tumor cells and establish long-term immune memory. Following immune checkpoint modulation therapy, cancer treatment vaccines may be an option worthy of clinical testing.

APA, Harvard, Vancouver, ISO, and other styles

Golshan, Aneesa, and George Hui. "Uptake and activation profile of murine dendritic cells in response to stimulation with functionalized iron oxide nanoparticles." Journal of Immunology 204, no. 1_Supplement (May 1, 2020): 91.20. http://dx.doi.org/10.4049/jimmunol.204.supp.91.20.

Full text

Abstract:

Abstract Subunit vaccines typically have better safety profiles than live attenuated or killed whole-cell vaccines, but are often less immunogenic and less efficacious when deployed alone. Thus, immunological adjuvants are frequently formulated with subunit vaccines to improve efficacy. However, few vaccine adjuvants are FDA-approved; and for many adjuvants their mechanisms of action are poorly understood. We previously explored the use of iron oxide (IO) nanoparticles (NPs) in subunit vaccine delivery and show that the IO NPs also possess adjuvant-like qualities, eliminating the need for additional adjuvants in the vaccine formulation. This study further dissects the mode of action of IO NPs as immunological adjuvants by examining the relationship of particle size and uptake on the activation profile of murine bone marrow derived dendritic cells (BMDCs) in response to in vitro stimulation with functionalized IO NPs. Using IO NPs of sizes ranging 5 – 30 nm, we showed by flow cytometry immunophenotyping that only IOs of 20nm and 30nm could induce an activated BMDC subset. The level of NP uptake by BMDCs, as measured by Prussian Blue staining, also varied with particle size, with IO of 5nm being the most efficiently internalized. Intriguingly, the levels of BMDC activation did not correlate with the level of IO NP uptake. We hypothesize only IO NPs taken up via selective endocytic pathways will activate BMDCs. The production of cytokine/chemokines by these BMDCs as further characterizations of the adjuvant-like profiles of IO NPs in relation to particle size and cellular uptake is currently being examined. These studies begin to dissect the mode of action of IO NPs as a self-adjuvanted vaccine delivery system on the innate-adaptive immune interface.

APA, Harvard, Vancouver, ISO, and other styles

Israeli, E., N. Agmon-Levin, M. Blank, and Y. Shoenfeld. "Adjuvants and autoimmunity." Lupus 18, no. 13 (October 30, 2009): 1217–25. http://dx.doi.org/10.1177/0961203309345724.

Full text

Abstract:

Some adjuvants may exert adverse effects upon injection or, on the other hand, may not trigger a full immunological reaction. The mechanisms underlying adjuvant adverse effects are under renewed scrutiny because of the enormous implications for vaccine development. In the search for new and safer adjuvants, several new adjuvants were developed by pharmaceutical companies utilizing new immunological and chemical innovations. The ability of the immune system to recognize molecules that are broadly shared by pathogens is, in part, due to the presence of special immune receptors called toll-like receptors (TLRs) that are expressed on leukocyte membranes. The very fact that TLR activation leads to adaptive immune responses to foreign entities explains why so many adjuvants used today in vaccinations are developed to mimic TLR ligands. Alongside their supportive role, adjuvants were found to inflict by themselves an illness of autoimmune nature, defined as ‘the adjuvant diseases’. The debatable question of silicone as an adjuvant and connective tissue diseases, as well as the Gulf War syndrome and macrophagic myofaciitis which followed multiple injections of aluminium-based vaccines, are presented here. Owing to the adverse effects exerted by adjuvants, there is no doubt that safer adjuvants need to be developed and incorporated into future vaccines. Other needs in light of new vaccine technologies are adjuvants suitable for use with mucosally delivered vaccines, DNA vaccines, cancer and autoimmunity vaccines. In particular, there is demand for safe and non-toxic adjuvants able to stimulate cellular (Th1) immunity. More adjuvants were approved to date besides alum for human vaccines, including MF59 in some viral vaccines, MPL, AS04, AS01B and AS02A against viral and parasitic infections, virosomes for HBV, HPV and HAV, and cholera toxin for cholera. Perhaps future adjuvants occupying other putative receptors will be employed to bypass the TLR signaling pathway completely in order to circumvent common side effects of adjuvant-activated TLRs such as local inflammation and the general malaise felt because of the costly whole-body immune response to antigen. Lupus (2009) 18, 1217—1225.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Immunological adjuvants"

O'Hagan, Derek Thomas. "Pharmaceutical formulations as immunological adjuvants." Thesis, University of Nottingham, 1987. http://eprints.nottingham.ac.uk/13211/.

Full text

Abstract:

The aim of this work was to enhance the immune responses to ovalbumin (OVA) following its oral administration, by the association of the protein with colloidal carriers, which may protect the protein from degradation in the gastrointestinal tract and/or facilitate its uptake across the intestine. An enzyme linked immunosorbent assay (ELISA) was established for the determination of rat anti-OVA antibodies and an immunisation protocol was established to induce a statistically significant salivary antibody response to OVA in the rat. A radioimmunoassay for the determination of rat anti-OVA antibodies was also established, to confirm the ELISA results. Methods were established to determine the extent of incorporation or adsorption of OVA into or onto the colloidal carrier formulations. OVA was incorporated into liposomes and polyacrylamide microparticles, and adsorbed to poly 2-butylcyanoacrylate particles, and gastrically intubated into separate groups of experimental rats. The primary and memory immune responses, both sera and saliva, were compared for each formulation with suitable control and blank groups. All colloidal carriers induced enhanced immune responses to OVA following oral administration in the rat, when compared with the respective control group responses. However, the enhancement for the liposomal group was not statistically significant when assessed in an Unpaired Student 't' test. The effect of particle size on the immune responses was assessed by the oral administration of 100 nm and 3pm poly 2-butylcyanoacrylate particles with adsorbed OVA. An electron microscopy study was undertaken with gold labelled poly 2-butylcyanoacrylate particles in an attempt to demonstrate the uptake of particles by M-cells overlying the Peyers' patches in the rat intestine.

APA, Harvard, Vancouver, ISO, and other styles

Almeida, Antonio J. L. "Particulate carriers as immunological adjuvants." Thesis, Aston University, 1993. http://publications.aston.ac.uk/12609/.

Full text

Abstract:

In recent years, much interest has focused on the significance of inducing not only systemic immunity but also good local immunity at susceptible mucosal surfaces. A new field of mucosal immunity has been established as information accumulates on gut-associated lymphoid tissue, bronchus-associated lymphoid tissue and nasal-associated lymphoid tissue (GALT, BALT and NALT, respectively) and on their role in both local and systemic immune responses. This project, following the line of investigation started by other workers, was designed to study the use of microspheres to deliver antigens by the mucosal routes (oral and nasal). Antigen-containing microspheres were prepared with PLA and PLGA, by either entrapment within the particles or adsorption onto the surface. The model protein antigens used in this work were mainly tetanus toxoid (TT), bovine serum albumin (BSA) and -globulins. In vitro investigations included the study of physicochemical properties of the particulate carriers as well as the assessment of stability of the antigen molecules throughout the formulation procedures. Good loading efficiencies were obtained with both formulation techniques, which did not affect the immunogenicity of the antigens studied. The influence of the surfactant employed on the microspheres' surface properties was demonstrated as well as its implications on the adsorption of proteins. Preparations containing protein adsorbed were shown to be slightly more hydrophobic than empty PLA microspheres, which can enhance the uptake of particles by the antigen presenting cells that prefer to associate with hydrophobic surfaces. Systemic and mucosal immune responses induced upon nasal, oral and intramuscular administration have been assessed and, when appropriate, compared with the most widely used vaccine adjuvant, aluminium hydroxide.

APA, Harvard, Vancouver, ISO, and other styles

White, Karen Louise, and n/a. "Modified liposomes as adjuvants." University of Otago. School of Pharmacy, 2005. http://adt.otago.ac.nz./public/adt-NZDU20070126.131417.

Full text

Abstract:

Despite the progress in elucidating antigens for both therapeutic and prophylactic vaccines, safety concerns over current vaccine delivery vehicles and adjuvants has limited the development of new vaccines. In particular, there is an urgent need for effective vaccines capable of stimulating cytotoxic T lymphocyte (CTL) responses against intracellular pathogens or tumor cells. Liposomes are under investigation as a particulate vaccine delivery system with the required safety profile and demonstrated ability to target antigens to dendritic cells (DC), the cells of the immune system responsible for initiating effective and long lasting CTL immune responses. Unmodified liposomes however, are inherently non-immunogenic and thus not capable of stimulating activation of DC, which is a necessary step in immune activation. In this thesis the use of modified liposomes to more efficiently target vaccine antigens to DC and then activate the DC sufficiently to initiate down-stream immune responses was investigated. In the first approach to liposome modification, mannosylated phospholipids were incorporated within the liposome bilayer to target C-type lectins on DC. Incorporation of mono- or tri-mannosylated phospholipids within liposomes was found to be an effective means of attaching mannose-containing ligands to the liposome surface without compromising the integrity of the liposome structure. The uptake of tri-mannose-containing liposomes was enhanced in human monocyte derived DC (MoDC) compared to both unmodified liposomes and mono-mannose-containing liposomes. In contrast, neither mono- nor tri-mannose-containing liposomes were taken up by murine bone marrow derived DC (BMDC) to a greater extent than unmodified liposomes. This finding may reflect the differences in ligand specificity for C-type lectins on DC derived from different mammalian species. It was also found in these studies that increased uptake of liposomal antigens by DC does not necessarily result in increased DC activation, as evidenced by a lack of up-regulation of DC surface activation markers and ability to stimulate T cell proliferation. The second approach to liposome modification involved the incorporation of lipid core peptides (LCPs) into the liposome structure. LCPs alone were demonstrated to be able to stimulate DC and subsequent CD8+ T cell activation in vitro. LCP-based vaccines were also able to stimulate effective cytotoxic immune responses in vivo, and protect against tumor challenge, but only if administered in alum with CD4 help. Liposomes containing LCPs were able to stimulate greater DC activation and subsequent CD8+ T cell proliferation in vitro compared with unmodified liposomes. In the in vivo studies however, LCP-containing liposomes were not able to stimulate a cytotoxic immune response or protect against tumor challenge as effectively as LCP administered in alum. In the final approach to liposome modification, inclusion of the adjuvant Quil A was investigated for its ability to increase the immunogenicity of LCP-containing liposomes. It was found that small amounts of Quil A could be incorporated into liposomes without compromising the liposome bilayer. The inclusion of as little as 2% Quil A was able to stimulate DC activation and subsequent T cell proliferation in in vitro studies. In addition, immunisation of mice with LCP-containing liposomes with incorporated Quil A was found to stimulate an in vivo CTL immune response comparable to LCPs administered under optimal vaccine conditions. In conclusion, the work presented in this thesis demonstrates that modified liposomes are a useful vaccine delivery system for the initiation of in vivo cytotoxic and prophylactic immune responses.

APA, Harvard, Vancouver, ISO, and other styles

Svelander, Lena. "Studies on immunological mechanisms of induced arthritis in the rat /." Stockholm, 2002. http://diss.kib.ki.se/2002/91-7349-349-X/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Fong, Long-yan, and 方朗茵. "Immunomodulatory properties of probiotic bacteria." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/208173.

Full text

Abstract:

Probiotics are living microorganisms, which when administered in adequate amounts confer a health benefit on the host. They have been reported to relieve acute diarrhoea, atopic dermatitis and irritable bowel syndrome in disease-specific animal studies and in human intervention trials. However, probiotics are regularly consumed by general healthy population with limited knowledge in the immunomodulation of probiotics of local and systemic immune responses in healthy experimental models. Serving as the first line of defense against microbial infections and the largest immunological organ in animal host, the epithelium lining the small and large intestine is supposed to be the first organ to encounter probiotics as probiotics are always orally taken. It is believed that probiotics regulate the local immunities in the gut, which acts as the pivot in modulating the systemic immune responses. Accordingly, it was hypothesized that probiotic bacteria can modulate both local and systemic immune responses in healthy population; and the immunomodulation of combination of probiotics is different from that of individual strains. Wildtype healthy C57BL/6 mice were fed with different probiotic strains − Lactobacillus rhamnosus GG (LGG), Lactobacillus rhamnosus LC705 (LC705), Bifidobacterium breve Bb99 (Bb99), Propionibacterium freudenreichii ssp. shermanii JS (PJS) or Escherichia coli Nissle 1917 (EcN), or mixture of probiotics − GGmix (LGG, LC705, Bb99 and PJS) and ECPJSmix (PJS and EcN), for three weeks. After that, intestine, liver, spleen and blood were investigated. Probiotics suppressed intestinal T helper (Th)17 immune response but enhanced systemic (hepatic and splenic) Th17 immune response, suggesting that immune homeostasis was maintained in healthy individuals. Mechanism of action of LGG was further studied in this project as LGG is the widely studied probiotics. It was hypothesized that LGG exerts immunomodulatory effects by bacteria cells and/or its derived soluble factors such as lactic acid. Immunomodulatory effects of LGG cells and their soluble factors on dendritic cells (DCs), macrophages and monocytes from healthy blood donors were investigated as antigen-presenting cells (APCs) are pivots of bridging innate and adaptive immunities. Cytokine secretion profile, expressions of toll-like receptors (TLRs) and activation-related receptors of the APCs were examined. Both LGG cells and their soluble factors promoted type 1-responsiveness while soluble factors promoted type 17-responsiveness as well. Yet, lactic acid seemed not to be the one which enhanced type 1 and type 17 immune responses in soluble factors. With better understanding on the immunomodulation of probiotics in healthy models, prophylactic efficacy of probiotics in preventing infections and diseases can be availed.
published_or_final_version
Biological Sciences
Doctoral
Doctor of Philosophy

APA, Harvard, Vancouver, ISO, and other styles

Gursel, Mayda. "Use of liposomes and cytokines as immunological adjuvants in vaccines." Thesis, University College London (University of London), 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.338640.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Chan, Wing-keung. "The immunomodulatory effects of purified b-glucans and b-glucan containing herbs." Click to view the E-thesis via HKUTO, 2007. http://sunzi.lib.hku.hk/HKUTO/record/B39557996.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Chan, Wing-keung. "The immunomodulatory effects of purified [beta]-glucans and [beta]-glucan containing herbs /." View the Table of Contents & Abstract, 2007. http://sunzi.lib.hku.hk/hkuto/record/B38724674.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Cheung, Ka-wai, and 張嘉瑋. "The immunomodulatory effect of Brazilian green propolis and its uniquecompound Artepillin C." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B45900231.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Roßmann, Laura [Verfasser]. "In-depth immunological analysis of prototypic adjuvants for vaccine formulations / Laura Roßmann." Mainz : Universitätsbibliothek der Johannes Gutenberg-Universität Mainz, 2020. http://d-nb.info/1223379299/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Immunological adjuvants"

Gregoriadis, Gregory, Anthony C. Allison, and George Poste, eds. Immunological Adjuvants and Vaccines. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4757-0283-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

NATO Advanced Study Institute on Immunological Adjuvants and Vaccines (1988 Ákra Soúnion, Greece). Immunological adjuvants and vaccines. New York: Plenum Press, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Gregory, Gregoriadis, McCormack Brenda, Allison Anthony C. 1925-, North Atlantic Treaty Organization. Scientific Affairs Division., and NATO Advanced Study Institute on Vaccines: New Generation Immunological Adjuvants (1994 : Akra Sounion, Greece), eds. Vaccines: New generation immunological adjuvants. New York: Plenum Press, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Almeida, Anton io Jose Leitao das Neves. Particulate carriers as immunological adjuvants. Birmingham: Aston University. Department of Pharmaceutical Sciences, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

K, Gupta V. Immune-modulation & vaccine adjuvants. Houston, Tex: Studium Press LLC, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

P, Chow Paul N., Grant Cynthia A, and Hinshalwood Anne M, eds. Adjuvants and agrochemicals. Boca Raton, Fla: CRC Press, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

International, Congress on Neo-Adjuvant Chemotherapy (1st 1985 Paris France). Neo-adjuvant chemotherapy =: Chimiothérapie néo-adjuvante : proceedings of the first International Congress on Neo-Adjuvant Chemotherapy held in Paris (France), 6-9 November, 1985. London: Libbey, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

International, Congress on Neo-Adjuvant Chemotherapy (2nd Paris France). Neo-adjuvant chemotherapy =: Chimiothérapie néo-adjuvante : proceedings of the Second International Congress on Neo-Adjuvant Chemotherapy held in Paris (France), 19-21 February 1988. London: Libbey, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

1945-, Benvenuto Antonio, ed. Immunologic adjuvant research. Hauppauge, NY: Nova Science, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Ichiro, Azuma, and Jolles G, eds. Immunostimulants: Now and tomorrow. Tokyo: Japan Scientific Societies Press, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Immunological adjuvants"

Allison, Anthony C., and Noelene E. Byars. "Immunological Adjuvants." In Genetically Engineered Vaccines, 133–41. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3410-5_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Heath, Andrew W. "Cytokines as Immunological Adjuvants." In Vaccine Design, 645–58. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1823-5_28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Mohagheghpour, N., M. Dawson, P. Hobbs, A. Judd, R. Winant, L. Dousman, N. Waldeck, et al. "Glucans as Immunological Adjuvants." In Advances in Experimental Medicine and Biology, 13–22. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1891-4_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Gregoriadis, Gregory. "Liposomes as Immunological Adjuvants." In Targeting of Drugs 3, 59–68. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-2938-5_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Allison, Anthony C. "Antigens and Adjuvants for a New Generation of Vaccines." In Immunological Adjuvants and Vaccines, 1–12. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4757-0283-5_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Gregoriadis, Gregory, Lloyd Tan, and Qifu Xiao. "The Immunoadjuvant Action of Liposomes: Role of Structural Characteristics." In Immunological Adjuvants and Vaccines, 79–94. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4757-0283-5_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

van Rooijen, Nico, and Donghui Su. "Immunoadjuvant Action of Liposomes: Mechanisms." In Immunological Adjuvants and Vaccines, 95–106. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4757-0283-5_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Snippe, H., A. F. M. Verheul, and J. E. G. van Dam. "Liposomal Vaccine to Streptococcus Pneumoniae Type 3 and 14." In Immunological Adjuvants and Vaccines, 107–22. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4757-0283-5_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Alving, Carl R., Robert L. Richards, Michael D. Hayre, Wayne T. Hockmeyer, and Robert A. Wirtz. "Liposomes as Carriers of Vaccines: Development of a Liposomal Malaria Vaccine." In Immunological Adjuvants and Vaccines, 123–31. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4757-0283-5_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Hunter, Robert L., Beth Bennett, Devery Howerton, Steve Buynitzky, and Irene J. Check. "Nonionic Block Copolymer Surfactants as Immunological Adjuvants: Mechanisms of Action and Novel Formulations." In Immunological Adjuvants and Vaccines, 133–44. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4757-0283-5_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Immunological adjuvants"

Hamid, Fatima FH, Scott Schactler, Debra Walter, Hardik Amin, Minh Le, David Burkhart, Chenming Zhang, and Marco Pravetoni. "Deciphering immunological mechanisms underlying the efficacy of nanoparticle-based vaccines and novel adjuvants against Opioid Use Disorder (OUD)." In ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.283050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Circelli, Luisa, Annacarmen Petrizzo, Maria Tagliamonte, Regina Heidenreich, Maria Lina Tornesello, Franco M. Buonaguro, and Luigi Buonaguro. "Abstract A044: Immunological effects of a novel RNA-based adjuvant in liver cancer patients." In Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-a044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Zídek, Zdeněk, Antonín Holý, Daniela Franková, Evžen Buchar, and Zdeněk Jiřička. "Inhibition of rat adjuvant-induced arthritis by 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA; Adefovir): Immunological, biochemical and hematological correlates." In XIth Symposium on Chemistry of Nucleic Acid Components. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 1999. http://dx.doi.org/10.1135/css199902180.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Schoelch, Sebastian, Conrad Rauber, Moritz Koch, Jürgen Weitz, and Peter E. Huber. "Abstract 5389: 3M-011, a toll-like-receptor-7/8 agonist, as immunological adjuvans in combined therapy of gastrointestinal tumors." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5389.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Carpanese, D., I. Montagner, A. Dalla Pietà, V. Rossi, A. Penna, G. Zuccolotto, G. Pasut, A. Grigoletto, and A. Rosato. "P09.03 Hyaluronic acid as a new immunologic adjuvant in cancer: design of effective preventive and therapeutic vaccination strategies for HER2/neu-positive breast tumors." In iTOC8 – the 8th Leading International Cancer Immunotherapy Conference in Europe, 8–9 October 2021, Virtual Conference. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/jitc-2021-itoc8.53.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Mittendorf, EA, SA Perez, P. Tzonis, GT Clifton, A. Ardavanis, JP Holmes, E. Lekka, et al. "Abstract P2-20-03: Combination Immunotherapy for Breast Cancer Patients: Safety and Immunologic Data from a Phase II Trial Administering a HER2/neu-Derived Peptide vaccine (AE37+GM-CSF) Sequentially or Concurrently with Trastuzumab in the Adjuvant Setting." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p2-20-03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Immunological adjuvants"

Clements, John D. Oral Adjuvant Therapy in the Development of Immunological Protection Against Mucosal Pathogens. Fort Belvoir, VA: Defense Technical Information Center, July 1995. http://dx.doi.org/10.21236/ada302243.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!